Abbott's cardiomems™ hf system receives fda approval to support patients battling earlier-stage heart failure

Abbott park, ill., feb. 21, 2022 /prnewswire/ -- abbott (nyse: abt) today announced that the u.s. food and drug administration (fda) has approved an expanded indication for the company's cardiomems™ hf system to support the care of more people living with heart failure.

ABT Ratings Summary

ABT Quant Ranking